Kiro
Kiro is the first AI-powered digital health platform for clinical biology in Europe. The company uses medical-grade artificial intelligence and cloud technology to leverage laboratory results and bring better outcomes for patients. Developed in partnership with leading laboratories, hospitals and physicians, and already used by millions, Kiro’s solutions provide personalized and easy-to-understand results for patients and caregivers while helping healthcare providers improve treatment for patients with real-time clinical decision support tools.
Sector
Digital Medicine
Location
Paris
Strategies
Digital Medicine
Status
Live
Website
www.kiro.bio
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.